8-K: Synergy CHC Reports 11th Profitable Quarter, Revenue Growth

Synergy CHC Corp. announced its third quarter 2025 financial results, marking its eleventh consecutive quarter of profitability with double-digit revenue growth and significant gross margin expansion.

Summary

• Reported third quarter 2025 financial results, marking the eleventh consecutive quarter of profitability.
• Revenue increased by 12.4% to $8.0 million for Q3 2025, up from $7.1 million in Q3 2024.
• Gross margin expanded by 370 basis points to 70.9% in Q3 2025, compared to 67.2% in Q3 2024, driven by a favorable product mix.
• Income from operations grew by 21.8% to $1.28 million in Q3 2025, from $1.05 million in Q3 2024.
• Net income for Q3 2025 was $125.3 thousand, a decrease from $783.6 thousand in Q3 2024.
• Earnings per share (EPS) for Q3 2025 was $0.01, down from $0.11 in Q3 2024.
• Adjusted EBITDA increased by 13.4% to $1.52 million in Q3 2025, up from $1.34 million in Q3 2024.
• Completed a $4.4 million public offering of common stock in August 2025, enhancing working capital.
• Reduced outstanding liabilities by $3.3 million during the third quarter.
• Working capital improved significantly to a surplus of $16.68 million as of September 30, 2025, from a $1.12 million deficit as of December 31, 2024.
• Appointed Teresa Thompson, a former Costco executive, to the Board of Directors on September 22, 2025.
• FOCUSfactor was named the #1 Pharmacist Recommended OTC Memory Supplement for 2025-2026 by Pharmacy Times.

Sentiment

Score: 6

Explanation: While the company achieved revenue growth, gross margin expansion, and improved working capital, the significant decline in net income and EPS, along with increased cash burn from operations, presents a mixed picture. The strategic wins and liability reduction are positive, but the bottom-line performance is a concern, despite management's positive framing.

Positives

• Achieved eleventh consecutive quarter of profitability.
• Reported double-digit revenue growth of 12.4% to $8.0 million in Q3 2025.
• Gross margin expanded significantly by 370 basis points to 70.9% due to favorable product mix.
• Income from operations increased by 21.8% to $1.28 million.
• Adjusted EBITDA grew by 13.4% to $1.52 million.
• Secured new retail and distribution partnerships for FOCUSfactor with major retailers like Kroger and Wakefern, expanding U.S. footprint.
• Successfully completed a $4.4 million public offering, strengthening working capital.
• Reduced outstanding liabilities by $3.3 million during the quarter.
• Improved working capital from a $1.12 million deficit to a $16.68 million surplus.
• Strengthened corporate governance with the appointment of former Costco executive Teresa Thompson to the Board of Directors.
• FOCUSfactor brand recognized as the #1 Pharmacist Recommended OTC Memory Supplement for 2025-2026.

Negatives

• Net income significantly decreased to $125.3 thousand in Q3 2025 from $783.6 thousand in Q3 2024.
• Earnings per share (EPS) dropped to $0.01 in Q3 2025 from $0.11 in Q3 2024.
• EBITDA slightly decreased to $1.31 million in Q3 2025 from $1.33 million in Q3 2024.
• Adjusted EBITDA per share decreased to $0.15 in Q3 2025 from $0.18 in Q3 2024.
• Operating expenses increased by 17.7% to $4.4 million, primarily due to costs associated with being a public company and launching the beverage division.
• Cash used in operating activities for the nine months ended September 30, 2025, increased to $3.21 million from $1.38 million in the prior year, attributed to liability reduction and higher inventory investment for the beverage division.

Risks

• Forward-looking statements are subject to risks, uncertainties, and other factors, many of which are outside of Synergy's control, that could cause actual results to differ materially from expectations.
• New factors emerge over time, and it is not possible for Synergy to predict all such factors.
• Investors should consider risk factors and other cautionary statements detailed in Synergy's filings with the SEC.

Future Outlook

The company is well positioned for growth in the fourth quarter and beyond, expecting continued brand expansion and growth initiatives. Management believes these efforts will create meaningful value for shareholders.

Management Comments

• "We are pleased to report our 11th quarter of profitability and double-digit revenue growth, accompanied by over 300 basis points of gross margin expansion." Jack Ross, CEO
• "We made meaningful progress across our strategic priorities by expanding retail authorizations and distribution partnerships for our FOCUSfactor functional beverages and shots." Jack Ross, CEO
• "Key partnerships with leading retailers, including Kroger and Wakefern, are strengthening our reach across North America." Jack Ross, CEO
• "We completed a $4.4 million public offering in August, providing us with added working capital to support continued growth and brand expansion." Jack Ross, CEO
• "With this added flexibility, along with our retail and distribution efforts, we’re well positioned for growth in the fourth quarter and beyond, which we believe will create meaningful value for our shareholders." Jack Ross, CEO

Industry Context

Synergy CHC operates in the growing consumer health and wellness market, specifically targeting brain health supplements and functional beverages with its FOCUSfactor brand, and women's wellness with Flat Tummy. The expansion into major retail channels like grocery, pharmacy, and convenience, along with the recognition as a top pharmacist-recommended product, indicates strong positioning within a competitive and expanding industry driven by consumer demand for health-focused products. The launch of a beverage division aligns with broader industry trends towards functional foods and drinks.

Comparison to Industry Standards

• The company's FOCUSfactor brand being named the #1 Pharmacist Recommended OTC Memory Supplement for 2025-2026 by Pharmacy Times indicates strong brand recognition and professional trust, suggesting a leading position within its specific niche of memory supplements.
• Strategic partnerships with major retailers such as Kroger and Wakefern, along with regional distributors like EG America, AlaBev, and Atlantic Importing, demonstrate successful market penetration and distribution expansion comparable to established players in the consumer packaged goods and health supplement sectors.
• The consistent profitability for eleven consecutive quarters, coupled with double-digit revenue growth and gross margin expansion, suggests a robust operational model that is performing well relative to many smaller to mid-sized companies in the highly competitive health and wellness industry.

Management Changes

Corporate Governance

Related Party Transactions

• Loan receivable (related party) of $4,407,449 as of September 30, 2025, compared to $4,375,059 as of December 31, 2024.
• Prepaid expenses include related party amounts of $1,050,212 as of September 30, 2025, compared to $312,966 as of December 31, 2024.
• Accounts payable and accrued liabilities include payable to shareholder of $88,770 as of September 30, 2025, compared to $88,644 as of December 31, 2024.
• Advances from related party of $135,000 for the nine months ended September 30, 2025, with repayments of $135,000.

Stakeholder Impact

• Shareholders: Potential for increased value from strategic growth initiatives and improved working capital, but diluted earnings per share and lower net income could be a concern. The public offering also diluted existing shares.
• Employees: Growth in the beverage division and expanded distribution may lead to increased opportunities.
• Customers: Expanded distribution through new retail partnerships (Kroger, Wakefern) makes FOCUSfactor products more accessible. Recognition as a top pharmacist-recommended product enhances trust.
• Suppliers: Increased inventory investment for the beverage division suggests higher demand for raw materials and manufacturing services.
• Creditors: Significant reduction in outstanding liabilities and improved working capital position strengthens the company's financial health and ability to meet obligations.

Next Steps

• Host a conference call on November 13, 2025, at 9:00 a.m. ET / 6:00 a.m. PT to discuss the financial results.
• Continue brand expansion and growth initiatives, particularly for FOCUSfactor functional beverages and shots.
• Leverage new retail and distribution partnerships to drive meaningful gains in late 2025 and beyond.
• Continue to manage operating expenses, especially those related to public company status and the beverage division launch.

Key Dates

Recommendation

While Synergy CHC Corp. demonstrated strong top-line growth, gross margin expansion, and significant improvements in working capital and liability reduction, the substantial decline in net income and earnings per share is a notable concern. The increase in operating expenses and cash used in operations, partly due to strategic investments in the beverage division and public company costs, suggests a period of reinvestment. The recent capital raise provides flexibility, and new distribution wins are positive for future revenue. However, the immediate impact on profitability warrants a cautious 'hold' stance until there is clearer evidence that these investments translate into improved bottom-line performance and sustainable EPS growth.

Keywords

Synergy CHC Corp, SNYR, Financial Results, Q3 2025, Earnings, Profitability, Revenue Growth, Gross Margin, Adjusted EBITDA, FOCUSfactor, Consumer Health, Wellness, Supplements, Functional Beverages, Retail Partnerships, Public Offering, Corporate Governance, Board Appointment, Working Capital